search

European Heart Journal - Quality of Care and Clinical Outcomes, Volume 7, Issue 5, November 2021, Pages 438–446, https://doi.org/10.1093/ehjqcco/qcab053

Published: 30 August 2021

Journal Article

Guided and unguided de-escalation from potent P2Y₁₂ inhibitors among patients with acute coronary syndrome: a meta-analysis

PDF

Anne H Tavenier and others

in European Heart Journal - Cardiovascular Pharmacotherapy

European Heart Journal - Cardiovascular Pharmacotherapy, Volume 8, Issue 5, September 2022, Pages 492–502, https://doi.org/10.1093/ehjcvp/pvab068

Published: 30 August 2021

Supplementary data

Modify your search

Availability

NARROW

Format

Subject

Type

Collection

Journal

Series

Publication date

Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial

Predictive value of the thrombotic risk criteria proposed in the 2023 ESC guidelines for the management of ACS: insights from a large PCI registry

Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study

Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding

Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial

Efficacy and safety of P2Y₁₂ inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis

481 VITAMIN K ANTAGONISTS, DIRECT ORAL ANTICOAGULANTS, OR LEFT ATRIAL APPENDAGE CLOSURE FOR PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

761 PRASUGREL OR CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES AT DIFFERENT THROMBOTIC RISK: RESULTS FROM THE PROMETHEUS STUDY

Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials

Subjective angina or myocardial ischaemia to justify PCI? Never mistake the finger for the moon

Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside

Perioperative management of P2Y₁₂ inhibitors in patients undergoing cardiac surgery within 1 year of PCI

Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD

SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis

456 Monotherapy with a P2Y12 inhibitor or aspirin for patients with established atherosclerosis: an updated meta-analysis

291 Ticagrelor monotherapy after percutaneous coronary intervention in high-risk patients with prior myocardial infarction: a prespecified twilight substudy

Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR

First and recurrent events in the ISCHEMIA trial: two sides of the same coin

Types of myocardial injury and mid-term outcomes in patients with COVID-19

Guided and unguided de-escalation from potent P2Y₁₂ inhibitors among patients with acute coronary syndrome: a meta-analysis

Modify your search

Publication date

This Feature Is Available To Subscribers Only